Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in a key phase III clinical trial

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019